Abstract
The effects of single oral doses of nabilone, a synthetic cannabinoid, were studied in four anxious volunteer subjects. Each subject had two exposures to placebo and three dose levels of nabilone at 1 week intervals in a single blind balanced Latin square design after the nabilone dose range was determined by each subject's response to a test dose. The Profile of Mood States (POMS), a self-rating adjective checklist, was used as the quantitative measure of subjective effects. The subjects performed a continuous avoidance procedure. High doses (4 or 5 mg) or nabilone produced orthostatic hypotension. Small dose-related increases in heart rate also occurred. Despite the occurrence of highly significant levels of subjective sedation, there were no significant effects of nabilone on behavior maintained by the continuous avoidance procedure. Two of these subjects experienced an anti-anxiety effect from low (1 or 2 mg) nabilone doses, but there was no statistically significant effect on the mean POMS anxiety factor for the group as a whole. In a follow-up experiment, four other anxious subjects received comparatively lower doses of nabilone. In these subjects there were no important effects on blood pressure or heart rate, and also no anti-anxiety effects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bass BM (1956) Development and evaluation of a scale for measuring social acquiescence. J Abnorm Soc Psychol 53:296–299
Brauzer B, Goldstein BJ (1973) Symptomatic volunteers: Another patient dimension for clinical trials. J Clin Pharmacol 13:89–98
Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi S (1974) The Hopkins symptom checklist (HSCL): A measure of primary symptom dimensions. In: Pichot P (ed) Psychological measurements in psychopharmacology: Modern problems in pharmacopsychiatry, vol 7. Karger, Basel
Drew WG, Miller LL (1974) Cannabis: Neural mechanisms and behavior — a theoretical review. Pharmacology 11:12–23
Dysken MW, Merry W, Davis JM (1978) Anticholinergic psychosis. Psychiatric Annals 8:452–456
El-Yousef MK, Janowsky DS, Davis JM, Rosenblatt JE (1973) Induction of severe depression by physostigmine in marijuana intoxicated individuals. Br J Addict 68:321–325
Eysenck HJ, Eysenck SBG (1968) Eysenck personality iventory. Educational and Industrial Testing Service. San Diego, California
Fabre LF, McLendon DM, Stark P (1978) Nabilone, a cannabinoid, in the treatment of anxiety: An open-label and double-blind study. Curr Ther Res 24:161–169
Fischman MW, Schuster CR (1979) The effects of chlorpromazine and pentobarbital on behavior maintained by electric shock or point loss avoidance in humans. Psychopharmacology 66:3–11
Fischman M, Smith R, Schuster CR (1976) The effects of chlorpromazine on avoidance and escape responding in humans. Pharmacol Biochem Behav 4:111–114
Freeman FR, Rosenblatt JE, El-Yousef M (1975) Interaction of physostigmine and delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther 17:121–126
Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochloperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300:1295–1297
Ilaria RL, Fann WE (1978) Nabilone, a cannabinol derivative, in anxiety neurosis. Fed Proc 37:619
Lemberger L, Rowe H (1975) Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther 18:720–726
Low MD, Klonoff H, Marcus A (1973) The neurophysiological basis of the marijuana experience. Can Med Assoc J 108:157–164
McCarthy LE, Borison HL (1977) Antiemetic activity of nabilone, a cannabinol derivative, reversed by naloxone in awake cats. Pharmacologist 19:230
McNair DM, Kahn JR, Droppleman LF, Fisher S (1968) Patient acquiescence and drug effects. In Rickels K (ed) Non-specific factors in drug therapy. C. C. Thomas, Springfield, Illinois
McNair DM, Lorr M, Droppleman LF (1971) Profile of mool states. Educational and Industrial Testing Service, San Diego, California
Nakano S, Gillespie HK, Hollister LE (1978) A model for evaluation of anti-anxiety drugs with the use of experimentally induced stress: Comparison of nabilone and diazepam. Clin Pharmacol Ther 23:54–62
National Institute on Drug Abuse (1975) Marijuana and health. Fifth report to the U. S. Congress, United States Government Printing Office, Washington D. C.
Prusoff B, Klerman GL (1974) Differentiating depressed from anxious neurotic outpatients. Arch Gen Psychiatry 30:302–309
Raskin A, Schilterbrandt J, Reatig N, McKeon JJ (1969) Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. J Neur Ment Disorders 148:87–98
Stark P, Archer RA (1975) Preclinical pharmacologic profile of a psychoactive cannabinoid. Pharmacologist 17:210
Uhlenhuth EH (1977) Evaluating anti-anxiety agents in humans: Experimental paradigms. Am J Psychiatry 134:659–662
Uhlenhuth EH, Stern M, Schuster CR, Domizi D (1975) Diazepam: Efficacy and toxicity as revealed by a small sample research strategy. In: Sudilovsky A, Gershon S, Beer B (eds) Predictability in psychopharmacology: Preclinical and clinical correlations. Raven Press, New York
Wagenaar WA (1969) Note on the construction of digram-balanced Latin squares. Psychol Bull 72:384–386
Williams EJ (1949) Experimental designs balanced for the estimation of residual effects of treatments. Austr J Scientific Res A 2:149–168
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Glass, R.M., Uhlenhuth, E.H., Hartel, F.W. et al. A single dose study of nabilone, a synthetic cannabinoid. Psychopharmacology 71, 137–142 (1980). https://doi.org/10.1007/BF00434401
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00434401